Key result
Abciximab therapy during coronary angioplasty resulted in a case of acute profound thrombocytopenia (platelet count: 800/mm3) at 16 hours, which improved rapidly with platelet transfusion.
Why the study?
Does abciximab therapy during coronary angioplasty cause acute profound thrombocytopenia?
Case Report (n=1)
Does abciximab therapy during coronary angioplasty cause acute profound thrombocytopenia?
Abciximab therapy during coronary angioplasty can cause unpredictable acute profound thrombocytopenia, necessitating periodic platelet count evaluation.
Answers are grounded in this paper and cite their sources.
Abciximab may trigger acute profound thrombocytopenia; this case leaves open incidence and monitoring needs in larger cohorts.
Since the extensive use of abciximab, a potent antiplatelet agent directed against GP IIb/IIIa platelet receptors, to prevent ischemic complications of percutaneous transluminal coronary angioplasty, few cases of thrombocytopenia have been observed. This paper reports a case of acute profound thrombocytopenia (platelet count: 800/mm3) occurring 16 h after abciximab therapy during coronary angioplasty. As thrombocytopenia occurrence is not predictable, platelet count should be evaluated periodically after drug administration. Mechanisms of this adverse effect remain unknown. Platelet transfusion results in a rapid and sustained improvement of platelet count, avoiding the occurrence of major hemorrhagic complications.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (1998) conducted a case report in Acute profound thrombocytopenia (n=1). Abciximab was evaluated on Acute profound thrombocytopenia. Abciximab therapy during coronary angioplasty resulted in a case of acute profound thrombocytopenia (platelet count: 800/mm3) at 16 hours, which improved rapidly with platelet transfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: